Cellular basis for bimatoprost effects on human conventional outflow

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 10, 2010, Pages 5176-5181

  Daniel Stamer, W ^a   Piwnica, David ^b   Jolas, Thierry ^b   Carling, Robert W ^c   Cornell, Clive L ^c   Fliri, Hans ^c   Martos, Jose ^c   Pettit, Simon N ^c   Wang, Jenny W ^d   Woodward, David F ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b CEREP   (France)

^c Selcia Ltd   (United Kingdom)

^d ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; AGN 211334; BIMATOPROST; CHOLERA TOXIN; CICAPROST; FLUPROSTENOL; PERTUSSIS TOXIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN F2 ALPHA; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; ACTIN; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

AQUEOUS HUMOR OUTFLOW; ARTICLE; CELL ACTIVATION; CELL CULTURE; CILIARY BODY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; HUMAN; HUMAN CELL; INTRAOCULAR PRESSURE; MUSCLE FIBER CONTRACTION; PRIORITY JOURNAL; SCHLEMM CANAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRABECULAR MESHWORK; ADULT; AGED; AQUEOUS HUMOR; CORNEA; DONOR; DOSE RESPONSE; DRUG ANTAGONISM; IMPEDANCE; INFANT; METABOLISM; MIDDLE AGED; SECRETION; SMOOTH MUSCLE;

ACTINS; ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CELLS, CULTURED; CILIARY BODY; CLOPROSTENOL; CORNEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; HUMANS; INFANT; INTRAOCULAR PRESSURE; MIDDLE AGED; MUSCLE, SMOOTH; RECEPTORS, PROSTAGLANDIN; TISSUE DONORS; TRABECULAR MESHWORK;

EID: 77958127619     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4955     Document Type: Article

References (49)

1. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000; 130:429-440.
2. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15:119-126.
3. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 47 Suppl. 2002;1:S105-S115.
4. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106:997-1004, discussion 1004-1005.
5. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9: 134-142.
6. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
7. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
8. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of Xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134-1145.
9. Toris CB, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma. 2007;16:189-195.
10. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111: 1658-1662.
11. Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007;48:4107-4115.
12. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol. 2008;145:114-119.
13. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767-776.
14. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869-875.
15. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol 41 Suppl. 1997;2:S53-S59.
16. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
17. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887-3895.
18. Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci. 2004;45:4368-4377.
19. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)- isopropyl ester treatment. Arch Ophthalmol. 2001;119:1165-1170.
20. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419-4426.
21. Anthony T, Pierce K, Stamer D, Regan J. Prostaglandin FP receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315-321.
22. Thieme H, Schimmat C, Munzer G, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2 and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006;47:938-945.
23. Stamer WD, Roberts BC, Howell DN, Epstein DL. Isolation, culture and characterization of endothelial cells from Schlemm's canal. Invest Ophthalmol Vis Sci. 1998;39:1804-1812.
24. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611-617.
25. Hutchinson A, Coons S, Chou C-L, et al. Induction of angiogenic immediate early genes by activation of FP prostanoid receptors in cultured human ciliary smooth muscle cells. Curr Eye Res. 2010; 35:408-418.
26. Weinreb RN, Kim DM, Lindsey JD. Propagation of ciliary smooth muscle cells in vitro and effects of prostaglandin F2 alpha on calcium efflux. Invest Ophthalmol Vis Sci. 1992;33:2679-2686.
27. Peters MF, Knappenberger KS, Wilkins D, et al. Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs. J Biomol Screen. 2007; 12:312-319.
28. Crawford KS, Kaufman PL. Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys. Invest Ophthalmol Vis Sci. 1991;32:510-519.
29. Chen J, Senior J, Marshall K, et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br J Pharmacol. 2005;144: 493-501.
30. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305:772-785.
31. Woodward DF, Krauss AH, Wang JW, et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin- ethanolamides) in the feline iris. Br J Pharmacol. 2007; 150:342-352.
32. Liang Y, Li C, Guzman VM, et al. Comparison of prostaglandin F2α, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003;278:27267-27277.
33. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154: 1079-1093.
34. Sharif NA, Kelly CR, Williams GW. Bimatoprost (Lumigan®) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies. Prostaglandins Leukot Essent Fatty Acids. 2003;68:27-33.
35. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001;432: 211-213.
36. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229.
37. Nobles M, Benians A, Tinker A. Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci U S A. 2005;102:18706-18711.
38. Morrow JD, Minton TA, Mukundan CR, et al. Free radical-induced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem. 1994;269:4317-4326.
39. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877-44885.
40. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem. 2004;279:53036-53047.
41. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A. 1993;90:7656-60.
42. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452-457.
43. Verdonk E, Johnson K, McGuinness R, et al. Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev Technol. 2006;4:609-619.
44. Atienza JM, Yu N, Wang X, Xu X, Abassi Y. Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array. J Biomol Screen. 2006;11:634-643.
45. Yu N, Atienza JM, Bernard J, et al. Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem. 2006;78:35-43.
46. Peterson J, Tian B, Bershadsky A, et al. Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci. 1999; 931-941.
47. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029-1037.
48. Tian B, Kaufman PL. Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res. 2005;80:215-225.
49. Ramos RF, Sumida GM, Stamer WD. Cyclic mechanical stress and trabecular meshwork cell contractility. Invest Ophthalmol Vis Sci. 2009;50:3826-3832.